Abstract
Alzheimer’s disease (AD) is characterised by abnormal amyloid beta and tau processing. Previous studies reported that cerebrospinal fluid (CSF) total tau (t-tau) levels vary between patients. Here we show that CSF t-tau variability is associated with distinct impairments in neuronal plasticity mediated by gene repression factors SUZ12 and REST. AD individuals with abnormal t-tau levels have increased CSF concentrations of plasticity proteins regulated by SUZ12 and REST. AD individuals with normal t-tau, on the contrary, have decreased concentrations of these plasticity proteins and increased concentrations in proteins associated with blood-brain and blood CSF-barrier dysfunction. Genomic analyses suggested that t-tau levels in part depend on genes involved in gene expression. The distinct plasticity abnormalities in AD as signaled by t-tau urge the need for personalised treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been supported by ZonMW Memorabel grant programme 73305056 (BMT) and 733050824 (BMT and PJV), the Swedish Research Council (2018-02532, HZ), the European Research Council (681712, HZ) and Swedish State Support for Clinical Research (#ALFGBG-720931, HZ), the Alzheimerfonden (Grant no. AF-930934) and Dtiftelsen Gamla tjanarinnor (JG), and the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement 115372 (PJV, HZ, SV, IB). Statistical analyses were performed at the VUmc Alzheimer Center that is part of the neurodegeneration research program of the Neuroscience Campus Amsterdam. EMIF-AD MBD proteomic analyses were performed at the Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Sweden. The VUmc Alzheimer Center is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. HZ is a Wallenberg Academy Scholar. The Leuven cohort was funded by Stichting Alzheimer Onderzoek (#11020, #15005, #13007) and the Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek (IWT #135043). The Lausanne cohort was supported by the Swiss National Research Foundation SNF (#320030_141179). We thank Drs. Andre Franke and Michael Wittig as well as Mrs. Tanja Wesse and Sanaz Sedghpour Sabet for their help with the genome-wide genotyping experiments. We thank Dr. Fabian Kilpert for his help with the processing and management of the genome-wide genotyping data. Data was used for this project of which collection and sharing was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Samples and data were obtained from ongoing cohort studies. These studies were approved by local Ethical Review Boards at: Aristotle University of Thessaloniki Medical School Ethics Committee, Thessaloniki, Greece; Ethics Committee of the Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany; Ethics Committee at Karolinska Institutet, Stockholm, Sweden; Committee on Health Research Ethics, Region of Denmark; Medical ethics committee VU Medical Center, Amsterdam, The Netherlands; Maastricht University Medical Center, Maastricht, The Netherlands; Ethische commissie onderzoek UZ/KU Leuven, Leuven, Belgium; Research Ethics Committee Lausanne University Hospital, Lausanne, Switzerland; Central Clinical Research and Clinical Trials Unit (UICEC Sant Pau), Barcelona, Spain; Ethic and Clinical Research Committee Donostia, San Sebastian, Spain; ADNI is collaborative study of over 50 sites and was approved by an ethical standards committee on human experimentation at each participating institution (for more information see http://adni.loni.usc.edu/).Signed informed consent was obtained from all participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Layout and headings supplemental table 2c revised
Data Availability
Raw proteomic data has been deposited in the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier 10.6019/PXD019910.
